FDA clears Terumo’s CDI blood oxygen monitor

Terumo has received FDA 510(k) clearance for its CDI Blood Parameter Monitoring System 550, which adds real-time oxygen delivery monitoring to its 12 critical blood parameters.

Oxygen delivery measurements show how much oxygen is being delivered to a patient during a cardiopulmonary bypass. The company suggests that monitoring oxygen delivery has shown to reduce acute kidney injuries, which is a common complication of cardiac surgery.

“For more than 30 years, Terumo’s CDI Systems have been the most trusted and used continuous in-line blood gas monitors for critical blood parameters,” Robert DeRyke, president and CEO of Terumo Cardiovascular, said in a press release. “We are continuing to develop monitoring technologies for the cardiac OR – and beyond – that will improve patient outcomes and result in meaningful value for our customers.”

Terumo’s new CDI System 550 measures and calculates pH, pCO2, pO2, K+, temperature, SO2, hematocrit, hemoglobin, base excess, bicarbonate, oxygen consumption and oxygen delivery. The system also offers optical fluorescence technology, a high-visibility LCD screen, advanced probe design and IEC 60601-1 third edition compliance.

Only a Few More Days to Register for the most anticipated conference of the winter! DeviceTalks West is just a few days away. Join more than 300 of your peers for a day of world-class education, networking, and a technology exhibition featuring the leading companies in the industry. Don’t miss out on this premier opportunity to come together and share perspectives with the best of the best in the industry. REGISTER NOW Use code LASTCHANCE to save an additional 20%.